Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Familial Renal Glucosuria (FRG) is characterized by the presence of persistent isolated glucosuria in the absence of both generalized proximal tubular dysfunction and hyperglycemia. FRG is usually considered a benign entity as most patients are not affected by severe clinical consequences. Polyuria and enuresis and later a mild growth and pubertal maturation delay are the only manifestations that have been reported during a follow-up period of 30 years. Episodic dehydration and ketosis during pregnancy and starvation and an increased incidence of urinary tract infections have occasionally been reported in severe cases. FRG is caused by loss-of-function mutations in the gene SLC5A2 (16p11.2).
Features include sometimes findings: Enuresis nocturna. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 1 | Excessive hunger (polyphagia) |
SLC5A2 function has not been fully characterized.
Familial renal glucosuria is associated with mutations in the SLC5A2 gene on chromosome 16.
Genetic testing for SLC5A2 is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
23 publications have been identified in PubMed for familial renal glucosuria. Research spans Case Report / Case Series (55%), Review / Meta-Analysis (32%), and Basic Science / Preclinical (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 | 55% |
Data assembled from 7 of 12 sources · Last updated Oct 4, 2026, 6:17 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
7 |
32% |
Laboratory research | 2 | 9% |
Disease patterns and progression | 1 | 5% |
Zhang P (2026). [PMID: 41889395](https://pubmed.ncbi.nlm.nih.gov/41889395/). *Front Oncol*. [Case Report / Case Series]
Li H (2026). [PMID: 41918973](https://pubmed.ncbi.nlm.nih.gov/41918973/). *Front Endocrinol (Lausanne)*. [Epidemiology / Natural History]
Suthanthararajan S (2026). [PMID: 42130929](https://pubmed.ncbi.nlm.nih.gov/42130929/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Swarnim S (2025). [PMID: 40953854](https://pubmed.ncbi.nlm.nih.gov/40953854/). *BMJ case reports*. [Case Report / Case Series]
Konopásek P (2025). [PMID: 39651934](https://pubmed.ncbi.nlm.nih.gov/39651934/). *Minerva Pediatr (Torino)*. [Review / Meta-Analysis]
Oshita T (2025). [PMID: 40636245](https://pubmed.ncbi.nlm.nih.gov/40636245/). *J Rural Med*. [Case Report / Case Series]
Allaire P (2025). [PMID: 39412882](https://pubmed.ncbi.nlm.nih.gov/39412882/). *Kidney360*. [Review / Meta-Analysis]
Liu D (2025). [PMID: 40858733](https://pubmed.ncbi.nlm.nih.gov/40858733/). *Scientific reports*. [Basic Science / Preclinical]
Gulati A (2025). [PMID: 40272970](https://pubmed.ncbi.nlm.nih.gov/40272970/). *Kidney360*. [Review / Meta-Analysis]
Torun Bayram M (2025). [PMID: 40059893](https://pubmed.ncbi.nlm.nih.gov/40059893/). *World J Clin Pediatr*. [Review / Meta-Analysis]